Mihoko Yotsumoto

Dr. Mihoko Yotsumoto

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2012 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
MYMihoko Yotsumoto
Mihoko Yotsumoto
SHShotaro Hagiwara
Shotaro Hagiwara
AAAtsushi Ajisawa
Atsushi Ajisawa
JTJunko Tanuma
Junko Tanuma
TUTomoko Uehira
Tomoko Uehira
Seiji OkadaSeiji Okada
Seiji Okada

1 January 2009 in Internal Medicine
Verified
Journal Article
Open access
PDF file
MYMihoko Yotsumoto
Mihoko Yotsumoto
NINaoaki Ichikawa
Naoaki Ichikawa
MUMayumi Ueno
Mayumi Ueno
YHYumiko Higuchi
Yumiko Higuchi
NANaoko Asano
Naoko Asano
HKHikaru Kobayashi
Hikaru Kobayashi
A 49-year-old HIV-positive Japanese man was referred to our hospital for multiple skin nodules. Many plasmablastic atypical lymphocytes were observed in the peripheral blood. He was diagnosed with diffuse large B cell lymphoma (DLBCL) by a biopsy of the inguinal lymph node. IgH/MYC translocation was detected by in situ hybridization of the lymph node and chromosomal analysis of bone marrow cells showed 46, XY, t(8 ; 14)(q24 ; q32)add(14)(q32), der(21)t(1 ; 21)(q12 ; p11). He showed a transient response to multi-agent chemotherapy, and during the course of salvage chemotherapy, he died of urinary infection. This case has unique clinical features compared with previously reported DLBCLs with plasmablastic differentiation.

29 October 2022 in Journal of Infection and Chemotherapy
Verified
Journal Article
Open access
RSRyoko Sekiya
Ryoko Sekiya
TMTakashi Muramatsu
Takashi Muramatsu
AIAkito Ichiki
Akito Ichiki
YCYushi Chikasawa
Yushi Chikasawa
MBMasato Bingo
Masato Bingo
EKEi Kinai
Ei Kinai
Treatment with tenofovir alafenamide fumarate (TAF) is associated with body weight gain. However, little or no information is available on this issue in Asian populations. This single-center retrospective study included Japanese people living with HIV (PLWH) who satisfied the following criteria; 1) switching from TDF to TAF after HIV-suppression, 2) follow-up for ≥2 years while on TDF and TAF, and 3) no switching of the third antiretroviral agent. Changes in annual body weight and lipid profiles were compared between the TDF and TAF periods. Of 328 patients, dolutegravir (DTG) was used in 118 PLWH. Overall, no significant difference in weight gain was observed between TDF and TAF (0.76 vs. 0.9 kg/year, p = 0.331). In TAF-period, younger (<50 years of age) group showed significantly greater weight gain than older group (1.03 vs. 0.12 kg/year, p = 0.037). In DTG group, weight gain was larger in TAF-period (0.74 vs. 1.31 kg/year, p = 0.046), especially in younger subgroup (1.43 kg/year) compared with older one (-0.12 kg/year). Multivariate regression analysis showed that TAF was not associated with weight gain (estimates 0.201, p = 0.170) except for DTG group, whereas young age was associated with weight gain in all subjects (estimates -0.033/1 year older, p < 0.001), DTG, RAL, and EFV groups. In Japanese PLWH, annual body weight change was comparable in TDF- and TAF-period, while TAF plus DTG correlated with weight gain. Since young age was a key determinant of weight change, careful interpretation is needed for TAF-associated weight gain.

1 January 2013 in Kansenshogaku Zasshi
Verified
Journal Article
Open access
TMTakashi Muramatsu
Takashi Muramatsu
NYNaoki Yanagisawa
Naoki Yanagisawa
YCYushi Chikasawa
Yushi Chikasawa
ISIkuo Seita
Ikuo Seita
MYMihoko Yotsumoto
Mihoko Yotsumoto
MAMinoru Ando
Minoru Ando
The improved survival of subjects with human immunodeficiency virus (HIV) has been accompanied by an increased prevalence of chronic kidney disease (CKD). Epidemic of CKD among those with HIV has not yet been evaluated in multiple tertiary hospitals in Japan. A cross-sectional study was conducted in 2011 at Tokyo Metropolitan Komagome Hospital (TMKH) and Tokyo Medical University Hospital (TMUH). A total of 1482 HIV-infected subjects (1384 men, 98 female, mean age: 44.2 +/- 11.4 years old) were consecutively enrolled in the study. Random urine and blood samples were collected to study prevalence of CKD. CKD was diagnosed as a decrease in glomerular function and/or proteinuria and classified into 5 stages based on National Kidney Foundation guidelines. The estimated glomerular filtration rate based on serum creatinine was calculated using the 3-variable equation, constructed by the Japanese Society of Nephrology. Proteinuria was defined as > or = 1+ on urine dipstick examination. All electronic medical charts were reviewed to determine comorbidities, including hypertension and diabetes mellitus (DM). The proportion of subjects receiving tenofovir disoproxil fumarate (TDF) was investigated. Risk factors for CKD were determined using multivariate logistic regression analysis. The mean CD4 cell count was 487 +/- 216/microL and 80.5% had undetectable HIV-RNA level in the combined cohort. Of the 90.2% of subjects taking antiretroviral agents, 61.5% was using TDF. The prevalence of overall CKD and CKD > or = stage 3 was 12.9% and 6.7%, respectively, both of which were nearly 3-fold higher in the TMKH cohort (p < .0001). Mean age and proportional prevalent hypertension and DM were significantly higher in the TKMH cohort than in the TMUH cohort. Multivariate analysis showed significant CKD to be associated with age > or =50 years (odds ratio [OR], 2.81), hypertension (OR, 3.04), and DM (OR, 2.05). CKD prevalence was 12.9% among combined cohorts, but differed significantly between them. Differences in age distribution and the proportion of comorbidities, including hypertension and DM, are likely involved.

1 January 2011 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
MYMihoko Yotsumoto
Mihoko Yotsumoto
YYYasuyuki Yamamoto
Yasuyuki Yamamoto
KFKatsuyuki Fukutake
Katsuyuki Fukutake
KSKeiko Shinozawa
Keiko Shinozawa
WSWataru Sugiura
Wataru Sugiura
TMToshiaki Miura
Toshiaki Miura

11 July 2018 in Oncology Letters
Verified
Journal Article
Open access
PDF file
MYMihoko Yotsumoto
Mihoko Yotsumoto
YIYoshikazu Ito
Yoshikazu Ito
SHShotaro Hagiwara
Shotaro Hagiwara
YTYasuhito Terui
Yasuhito Terui
HNHirokazu Nagai
Hirokazu Nagai
Seiji OkadaSeiji Okada
Seiji Okada
There has been no comparative clinical study focused on differences in the clinical features of Epstein‑Barr virus (EBV)+ Hodgkin lymphoma (HL) between HIV‑positive and ‑negative cases. In a nationwide survey from 511 institutions in Japan, the present study investigated 16 EBV+ HIVpositive HL patients. To further clarify their characteristics in comparison with EBV+ HIVnegative HL (n=34) in the combination antiretroviral therapy era in Japan, the present study was performed. Results indicated that EBV+ HIVpositive HL frequently occurred in a younger population compared with EBV+ HIVnegative HL (P=0.0295), and that the EBV+ HIVpositive HL group was not associated with the nodular sclerosis subtype in the population who were below the age of 40. Notably, the EBV+ HIVpositive HL group had a significantly higher frequency of extra‑nodal involvement (P=0.0214), including marrow invasion. In the advanced stage, 80% of those with EBV+ HIVpositive HL did not require dose‑reduction and in the majority of cases, chemotherapy was completed. There were no significant differences in the complete remission rate (P=0.1961), overall survival (P=0.200) and progression‑free survival (P=0.245) between EBV+ HIVpositive HL (median observational period, 23.5 months) and EBV+ HIVnegative HL (median observational period, 64.5 months), suggesting that HIV positivity may not have a negative impact on the clinical outcome of EBV+ HL. Notably, standard chemotherapy is effective and tolerable for EBV+ HL, regardless of HIV infection.